BioSpecifics Technologies Corp. (NASDAQ: BSTC) was established in 1957 and is headquartered in Wilmington, Delaware. It has 7 full-time employees. It is a biopharmaceutical company that has developed injectables for various indications in the United States and internationally. The collagenase Clostridium tissue lysate.
BioSpecifics Technologies Corp. (BSTC):
BioSpecifics is a biopharmaceutical company that originated and continues to develop collagenase-based therapies. Collagenase is a natural enzyme that causes collagen to break down. Collagen is the main structural protein in the extracellular matrix in various connective tissues of the human body, and it is the protein with the highest content in mammals. The local accumulation of excess collagen is related to many medical conditions.
BioSpecifics Technologies has developed a first-class collagenase-based product, Clostridium Collagenase Tissue Lysis (CCH), which is sold in the United States under the XIAFLEX® trademark. XIAFLEX® is marketed in the United States by the company’s partner Endo for the treatment of Dupuytren contracture and Peyronie’s disease.
In addition to investing in the development of several potential new indications for collagenase-based technology, BioSpecifics also seeks to cooperate with companies that have rights in new technologies and products in specific markets.
BioSpecifics Technologies also provides injectable collagenase for the treatment of frozen shoulder, cellulite, canine lipoma, lateral hip fat, plantar fibromatosis, human lipoma and uterine fibroids.
BioSpecifics Technologies has signed a development and licensing agreement with Endo Global Ventures.